Prostate — In Follow-up

ENZARAD is a randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer.

Enzalutamide is a new hormone treatment taken as tablets. Previous trials have proven that enzalutamide improves survival and quality of life in patients with prostate cancer that have stopped responding to standard hormone treatments and chemotherapy. This large, international randomised trial will determine if treatment with enzalutamide can improve survival and quality of life in people starting radiation and hormone therapy for prostate cancer that does not seem to have spread beyond the prostate.

The trial has been led from Australia by ANZUP in collaboration with the NHMRC Clinical Trials Centre. The trial accrued 802 people from 69 sites across Australia, New Zealand, Canada, the US, Ireland, and the UK. Recruitment closed on 30th June 2018.

The ANZUP investigator initiated studies were financially supported by Astellas, who also provided enzalutamide.
If you think this trial might be right for you, please ask your doctor.
Trial Title
Enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer: a randomised phase III trial
Cancer Type
Trial Status
In Follow-up
Protocol Number
ANZUP 1303
Co-ordinating centre
Study Chair
Professor Scott Williams and Professor Paul Nguyen
Patient Population
Men with localised prostate cancer at high risk for recurrence deemed suitable for external beam radiation therapy
Detailed Information
Further Information
Participating Centres
Blacktown Hospital
Calvary Mater Newcastle
Campbelltown Hospital - South Western Sydney Local Health District
Central West Cancer Services
Chris O'Brien Lifehouse - Sydney Local Health District
GenesisCare Newcastle
Gosford Hospital
Liverpool Hospital - South Western Sydney Local Health District
Prince of Wales Hospital - South Eastern Sydney Health District
Royal North Shore Hospital - Northern Sydney Local Health District
St George Hospital - South Eastern Sydney Local Health District (SESLHD)
St Vincent's Hospital - Sydney
Sydney Adventist Hospital
North West Cancer Centre -Tamworth Hospital
Westmead Hospital - Western Sydney Local Health District
Wollongong Hospital

Austin Health
Eastern Health
Epping Radiation Oncology Centre (EPROC)
Genesiscare VIC - Frankstown
Peter MacCallum Cancer Centre - Bendigo
Peter MacCallum Cancer Centre - East Melbourne
Peter MacCallum Cancer Centre - Moorabbin
Genesiscare VIC - Ringwood
Sunshine Hospital
Western Radiation Oncology Centre (WROC) Footscray
Epworth Freemasons Hospital

Genesiscare QLD Tugun and Southport
Genesiscare QLD Wesley and Chermside
Nambour General Hospital
Oncology Research Australia, Toowoomba Hospital
Princess Alexandra Hospital
Radiation Oncology Centre - Gold Coast
Radiation Oncology Services – Mater Adult Hospital
Royal Brisbane & Women's Hospital
The Townsville Hospital

Ashford Cancer Centre Research
Flinders Medical Centre
Royal Adelaide Hospital - Central Adelaide Local Health Network Inc.

Royal Hobart Hospital

Fiona Stanley Hospital

Auckland City Hospital
Christchurch Hospital
Palmerston North Hospital

Addenbrookes Hospital
Charing Cross Hospital
Guy's and St. Thomas Hospital
Kent & Canterbury Hospital
Nottingham City Hospital - City Campus
The Royal Marsden Hospital
Royal United Hospitals Bath
University Hospital Southampton
University College London Hospitals
Velindre Cancer Centre
Western General Hospital

Beacon Private Hospital Dublin
Cork University Hospital
Galway University Hospital
Mater Misericordiae University Hospital
Mater Private Hospital
St. Lukes Hospital

AZ Groeninge Kortrijk - Campus Kennedylaan

Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute

Catalan Institute of Oncology (ICO) Badalona
Hospital Universitario de Salamanca
Hospital Donostia

University Hospital Salzburg

The Institute Of Oncology

Participating Centres